microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells

Mortoglou, Maria; Miralles, Francesc; Arısan, Elif Damla; Dart, Dafydd Alwyn; Jurčević, Stipo; Lange, Sigrun; Uysal-Onganer, Pinar

doi:10.3390/ijms23031275

Cited by 16 publications

(15 citation statements)

References 148 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miR-21 is an oncogenic microRNA that is dysregulated in pancreatic cancer. The exact mechanism behind its function in CSCs is unclear; however, the silencing of miR-21 resulted in a downregulation of CSCs and mesenchymal EMT markers, but an elevated expression of E-cadherin [ 112 , 113 ].…”

Section: Epigenetic Events In Pancreatic Cancer Stem Cellsmentioning

confidence: 99%

Cancer Stem Cells in Pancreatic Ductal Adenocarcinoma

Bubin

Uljanovs

Štrumfa

2023

IJMS

View full text Add to dashboard Cite

The first discovery of cancer stem cells (CSCs) in leukaemia triggered active research on stemness in neoplastic tissues. CSCs represent a subpopulation of malignant cells, defined by unique properties: a dedifferentiated state, self-renewal, pluripotency, an inherent resistance to chemo- and radiotherapy, the presence of certain epigenetic alterations, as well as a higher tumorigenicity in comparison with the general population of cancer cells. A combination of these features highlights CSCs as a high-priority target during cancer treatment. The presence of CSCs has been confirmed in multiple malignancies, including pancreatic ductal adenocarcinoma, an entity that is well known for its dismal prognosis. As the aggressive course of pancreatic carcinoma is partly attributable to treatment resistance, CSCs could contribute to adverse outcomes. The aim of this review is to summarize the current information regarding the markers and molecular features of CSCs in pancreatic ductal adenocarcinoma and the therapeutic options to remove them.

show abstract

Section: Epigenetic Events In Pancreatic Cancer Stem Cellsmentioning

confidence: 99%

Cancer Stem Cells in Pancreatic Ductal Adenocarcinoma

Bubin

Uljanovs

Štrumfa

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…In PDAC cell lines, for example, miR-21 was reported to modulate key stemness factors, such as CD44, CD133, C-X-C chemokine receptor type 4 (CXCR4), and aldehyde dehydrogenase 1 (ALDH1), and miR-21 knockout was shown to significantly downregulate these factors [ 75 ]. Overexpression of miR-21 in CRC cells led to the downregulation of PDCD4 and the transforming growth factor beta receptor 2 (TGFBR2).…”

Section: Regulation Of Stemness Markers and Differentiation By Micror...mentioning

confidence: 99%

From Molecular Mechanisms to Therapeutics: Understanding MicroRNA-21 in Cancer

Rhim

Baek

Seo

et al. 2022

Cells

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small noncoding RNAs that play an important role in regulating gene expression at a posttranscriptional level. As one of the first discovered oncogenic miRNAs, microRNA-21 (miR-21) has been highlighted for its critical role in cancers, such as glioblastoma, pancreatic adenocarcinoma, non-small cell lung cancer, and many others. MiR-21 targets many vital components in a wide range of cancers and acts on various cellular processes ranging from cancer stemness to cell death. Expression of miR-21 is elevated within cancer tissues and circulating miR-21 is readily detectable in biofluids, making it valuable as a cancer biomarker with significant potential for use in diagnosis and prognosis. Advances in RNA-based therapeutics have revealed additional avenues by which miR-21 can be utilized as a promising target in cancer. The purpose of this review is to outline the roles of miR-21 as a key modulator in various cancers and its potential as a therapeutic target.

show abstract

“…MiR-21 is of special interest, since it functions as an oncogene by down-regulating tumor suppressors PTEN , PDCD4 , TPM1 , and TIMP3 [ 22 ]. MiR-21 has been associated with tumorigenesis, invasion, metastasis [ 65 , 66 ], mesenchymal transition and stemness of PDAC cells, and has recently been suggested as a biomarker for PDAC aggressiveness [ 67 ].…”

Section: Alterations In Tumor Tissuementioning

confidence: 99%

Oncogenomic Changes in Pancreatic Cancer and Their Detection in Stool

et al. 2022

View full text Add to dashboard Cite

Pancreatic cancer (PC) is an aggressive malignancy with a dismal prognosis. To improve patient survival, the development of screening methods for early diagnosis is pivotal. Oncogenomic alterations present in tumor tissue are a suitable target for non-invasive screening efforts, as they can be detected in tumor-derived cells, cell-free nucleic acids, and extracellular vesicles, which are present in several body fluids. Since stool is an easily accessible source, which enables convenient and cost-effective sampling, it could be utilized for the screening of these traces. Herein, we explore the various oncogenomic changes that have been detected in PC tissue, such as chromosomal aberrations, mutations in driver genes, epigenetic alterations, and differentially expressed non-coding RNA. In addition, we briefly look into the role of altered gut microbiota in PC and their possible associations with oncogenomic changes. We also review the findings of genomic alterations in stool of PC patients, and the potentials and challenges of their future use for the development of stool screening tools, including the possible combination of genomic and microbiota markers.

show abstract

microRNA-21 Regulates Stemness in Pancreatic Ductal Adenocarcinoma Cells

Cited by 16 publications

References 148 publications

Cancer Stem Cells in Pancreatic Ductal Adenocarcinoma

Cancer Stem Cells in Pancreatic Ductal Adenocarcinoma

From Molecular Mechanisms to Therapeutics: Understanding MicroRNA-21 in Cancer

Oncogenomic Changes in Pancreatic Cancer and Their Detection in Stool

Contact Info

Product

Resources

About